Impact Biomedical (IBO) Total Debt (2022 - 2025)

Impact Biomedical (IBO) has reported Total Debt for 4 consecutive years, with $45.8 million the latest figure, recorded in Q3 2025.

• For the quarter ending Q3 2025, Total Debt rose 471.6% year-over-year to $45.8 million; the trailing twelve-month figure through Sep 2025 stood at $45.8 million (up 471.6% YoY), and the FY2024 full-year result was $21.0 million, down 13.24% from the prior year.
• Total Debt improved to $45.8 million in Q3 2025 per IBO's latest filing, from $44.7 million in the prior quarter.
• Across five years, Total Debt topped out at $45.8 million in Q3 2025 and bottomed at $8.0 million in Q3 2024.
• Historically, Total Debt has averaged $20.1 million across 4 years, with a median of $13.5 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Total Debt plunged 32.06% in 2024, then surged 471.6% in 2025.
• Over 4 years, Total Debt stood at $10.0 million in 2022, then surged by 141.7% to $24.1 million in 2023, then decreased by 13.24% to $21.0 million in 2024, then surged by 118.41% to $45.8 million in 2025.
• According to Business Quant data, Total Debt over the past three periods registered $45.8 million, $44.7 million, and $18.3 million for Q3 2025, Q2 2025, and Q1 2025 respectively.